RecruitingPhase 1NCT06464861

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma

Sequential Treatment With 7x19 CAR-T After Umbilical Cord Blood Derived CD19 CARNK in Relapsed/Refractory B Cell Lymphoma

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Enrollment

52 participants

Start Date

Jun 20, 2024

Study Type

INTERVENTIONAL

Conditions

Mantle Cell Lymphoma (MCL)Primary Mediastinal B-cell Lymphoma (PMBCL)

Summary

To study the safety and efficacy of cord blood-derived CD19 CAR-NK cells sequential with 7x19 CAR-T in relapse / refractory B cell lymphoma

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a two-step immune cell therapy approach for relapsed or treatment-resistant B-cell lymphoma. It uses NK cell therapy first (CARNK), followed by a CAR-T cell therapy, with the goal of improving response rates. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with diffuse large B-cell lymphoma or a related B-cell lymphoma - Your cancer has come back or stopped responding to at least 2 prior lines of treatment - Your cancer cells carry the CD19 or CD7/CD19 markers **You may NOT be eligible if...** - You have active uncontrolled infection - You have significant heart, lung, liver, or kidney problems - You have other active cancers Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.